#pharmaceutical

Biopharmaunternehmen strukturieren internationale Lizenzvereinbarungen neu, um ihr Risiko durch Most-Favored-Nation-Preisregeln zu verringern, die US-Arzneimittelpreise an die niedrigsten in anderen Ländern gezahlten Preise binden.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.